financetom
Business
financetom
/
Business
/
US, Israeli officials deny approving sale of Israeli spyware firm to US investors
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US, Israeli officials deny approving sale of Israeli spyware firm to US investors
Dec 20, 2024 2:29 PM

WASHINGTON (Reuters) - Officials in the United States and Israel have denied reports their countries had signed off on the sale of Israeli spyware maker Paragon to Florida-based AE Industrial Partners.

Over the past week, Israeli news outlets reported that Paragon, which was founded by former Israeli intelligence officers and backed by ex-Israeli Prime Minister Ehud Barak, had been bought by AE, an investment group focused on national security-related businesses. On Monday, a person familiar with the deal confirmed its broad outlines to Reuters.

Israeli media outlets, without citing sources, said the deal had secured the approval of American and Israeli officials.

But on Friday, a senior White House official said that was not true.

"The U.S. government never 'approved' this sale. This is a private transaction," the official said. "There wasn't some sort of green light given for this sale."

The Israeli military also denied the reports, according to local media, which quoted the Defense Ministry saying that while Paragon had been in touch about the purchase, "the Ministry of Defense did not approve the sale" and officials were still studying the transaction.

Emails seeking comment from AE and Paragon were not immediately returned. The Israeli military has not responded to several requests for comment.

Paragon has already tried to make inroads in the U.S. surveillance market, although not without meeting roadblocks. In September, U.S. Immigration and Customs Enforcement signed a one-year contract worth $2 million with Paragon's U.S. subsidiary, according to a report in Wired. But the White House official confirmed the contract had subsequently been paused and put under review.

ICE did not immediately return a message seeking comment.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Prologis beats core FFO estimates on improving warehouse demand
Prologis beats core FFO estimates on improving warehouse demand
Jan 21, 2025
(Reuters) - Real estate investment trust (REIT) Prologis ( PLD ) beat Wall Street expectations for fourth-quarter core funds from operations (FFO), helped by improving demand for its warehousing spaces and sale of a data center. Shares of the warehouse-focused REIT were up 3.3% in morning trade. Potential stocking activity by importers owing to the threat of new tariffs by...
What's Going On With Palantir Stock Tuesday?
What's Going On With Palantir Stock Tuesday?
Jan 21, 2025
Palantir Technologies Inc ( PLTR ) shares are trading higher on Tuesday. Here’s a look at what’s going on. What To Know: Palantir ( PLTR ) shares are getting a lift in early trading. It’s possible that buyers are stepping in after U.S. President Donald Trump revoked an executive order from 2023 that aimed to reduce the risks of AI...
Market Chatter: Goldman Sachs Rolls Out AI Assistant for Employees
Market Chatter: Goldman Sachs Rolls Out AI Assistant for Employees
Jan 21, 2025
10:28 AM EST, 01/21/2025 (MT Newswires) -- Goldman Sachs Group ( GS ) has released a program called GS AI assistant to about 10,000 employees and plans to roll out the generative artificial intelligence assistant to all its knowledge workers in 2025, CNBC reported Tuesday, citing Goldman Sachs ( GS ) Chief Information Officer Marco Argenti. The tool will initially...
Dermata, Revance Collaborate on Trial to Treat Chronic Armpit Sweating
Dermata, Revance Collaborate on Trial to Treat Chronic Armpit Sweating
Jan 21, 2025
10:28 AM EST, 01/21/2025 (MT Newswires) -- Dermata Therapeutics ( DRMA ) and Revance Therapeutics ( RVNC ) said Tuesday they signed a collaboration agreement for a clinical study that will evaluate the use of Dermata's xyngari with Revance's daxxify for the treatment of primary axillary hyperhidrosis, which is a chronic condition that causes excessive armpit sweating. The randomized 16-week...
Copyright 2023-2026 - www.financetom.com All Rights Reserved